Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 667-674

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Nakamuta, Makoto ^b   Kajiwara, Eiji ^c   Nomura, Hideyuki ^d   Dohm En, Kazufumi ^e   Takahashi, Kazuhiro ^f   Satoh, Takeaki ^g   Azuma, Koichi ^h   Kawano, Akira ⁱ   Tanabe, Yuichi ^j   Kotoh, Kazuhiro ^k   Shimoda, Shinji ^k   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^d Shin Kokura Hospital   (Japan)

^e CHIHAYA HOSPITAL   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g Kokura Medical Center   (Japan)

^h Kyushu Central Hospital   (Japan)

ⁱ KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^j Fukuoka City Hospital   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Anemia; Hepatitis C virus; Inosine triphosohatase; Pegylated interferon; Ribavirin; Telaprevir

Indexed keywords

HEMOGLOBIN; INOSINE PHOSPHATE; INOSINE TRIPHOSPHATASE; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ANEMIA; AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE; AUROC; CI; CONFIDENCE INTERVAL; EGFR; ESTIMATED GLOMERULAR FILTRATION RATE; HAZARD RATIO; HB; HCV; HEMOGLOBIN; HEPATITIS C VIRUS; HR; INOSINE TRIPHOSOHATASE; INOSINE TRIPHOSPHATASE; ITPA; PEGIFN; PEGYLATED INTERFERON; RAPID VIROLOGICAL RESPONSE; RBV; RIBAVIRIN; RVR; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SUSTAINED VIROLOGICAL RESPONSE; SVR; TELAPREVIR; TVR;

AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS;

EID: 84884411714     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.017     Document Type: Article

References (26)

1. C. Niederau, S. Lange, T. Heintges, A. Erhardt, M. Buschkamp, and D. Hürter Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1998 1687 1695 (Pubitemid 28549142)
2. J. Hayashi, N. Furusyo, I. Ariyama, Y. Sawayama, Y. Etoh, and S. Kashiwagi A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia J Infect Dis 181 2000 1523 1527 (Pubitemid 30387740)
3. E. Ogawa, N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, and T. Maruyama Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study J Hepatol 58 2013 495 501
4. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
5. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
6. N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, Y. Tanabe, and A. Masumoto Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group J Gastroenterol Hepatol 23 2008 1094 1104 (Pubitemid 352019379)
7. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
8. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. A.J. Muir, F.F. Poordad, J.G. McHutchison, M.L. Shiffman, T. Berg, and P. Ferenci Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response Hepatology 54 2011 1538 1546
11. J. Fellay, A.J. Thompson, D. Ge, C.E. Gumbs, T.J. Urban, and K.V. Shianna ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
12. H. Ochi, T. Maekawa, H. Abe, Y. Hayashida, R. Nakano, and M. Kubo ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients Gastroenterology 139 2010 1190 1197
13. K. Chayama, C.N. Hayes, H. Abe, D. Miki, H. Ochi, and Y. Karino IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C J Infect Dis 204 2011 84 93
14. C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526 (Pubitemid 36919874)
15. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C Hepatology 20 1994 15 20
16. E. Ogawa, N. Furusyo, K. Toyoda, H. Taniai, S. Otaguro, and M. Kainuma Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment BMC Gastroenterol 10 2010 38
17. P. Simmonds, A. Alberti, H.J. Alter, F. Bonino, D.W. Bradley, and C. Brechot A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology 19 1994 1321 1324 (Pubitemid 24134259)
18. N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, and H. Kumada Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C J Viral Hepat 19 2012 e134 142
19. N. Furusyo, E. Ogawa, M. Nakamuta, E. Kajiwara, H. Nomura, and K. Dohmen Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C J Hepatol 59 2013 205 212
20. E. Ogawa, N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, and Y. Tanabe Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study J Gastroenterol Hepatol 27 2012 1233 1240
21. E. Ogawa, N. Furusyo, M. Murata, H. Ikezaki, T. Ihara, and T. Hayashi Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1 J Hepatol 57 2012 534 540
22. N. Furusyo, E. Ogawa, M. Sudoh, M. Murata, T. Ihara, and T. Hayashi Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial J Hepatol 57 2012 1186 1192
23. S. Sumi, A.M. Marinaki, M. Arenas, L. Fairbanks, M. Shobowale-Bakre, and D.C. Rees Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency Hum Genet 111 2002 360 367 (Pubitemid 36075062)
24. H. Cao, and R.A. Hegele DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency J Hum Genet 47 2002 620 622 (Pubitemid 36083264)
25. J. Bierau, M. Lindhout, and J.A. Bakker Pharmacogenetic significance of inosine triphosphatase Pharmacogenomics 8 2007 1221 1228 (Pubitemid 47578231)
26. G. Stocco, M.H. Cheok, K.R. Crews, T. Dervieux, D. French, and D. Pei Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia Clin Pharmacol Ther 85 2009 164 172